🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  2. Disitamab Vedotin

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  3. ELRANATAMAB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  4. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous

    Bristol-Myers Squibb / Pfizer EEIG

    Melanoma

    phase 2 small molecule active

    1 trial

  6. FULVESTRANT, LETROZOLE

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HR-positive HER2-negative metastatic/advanced BC

    phase 2 small molecule active

    1 trial

  7. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb / Pfizer EEIG

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  8. Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 100 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)

    phase 2 small molecule active

    1 trial

  9. IPILIMUMAB, AXITINIB, PF-08634404, AXITINIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  10. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  11. LETROZOLE, FULVESTRANT

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  12. Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  13. MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  15. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  16. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  19. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  20. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  22. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  23. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb / Pfizer EEIG

    Pan tumor

    phase 2 small molecule active

    1 trial

  24. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources